Dr. Kevin Zorn

Dr. Kevin Zorn
Dr. Kevin Zorn is an associate professor of urology at the University of Montreal (CHUM), sub-specializing in robotic surgery and BPH surgical care. Dr. Zorn’s career has consistently been hallmarked by research and innovation. Among his many firsts, he was the first in Canada and Québec to use many new BPH technologies including Greenlight XPS, Rezum, iTind, Optilume, Aquablation, Zenflow and Urocross. He has also been the first in Canada to introduce cutting-edge technologies including the Clarius and ButterflyIQ point-of care ultrasound (POCUS), as well as disposable AMBU4 cystoscopes for faster patient care and safety. He is among the first physicians globally to be named as a Center of Excellence for Rezum and Greenlight vaporization and VIT (vapor incision technique). He is an international speaker and surgical trainer for these techniques. Dr. Zorn is the senior author of the Male LUTS/BPH guidelines for the 2018 and 2022 Canadian Urological Association and has been an invited reviewer of the American Urological Association BPH guidelines. He has also helped create national online programs in robotic prostate cancer care and rehabilitation as well as a BPH patient decision aid tool. Over the past 17 years, he has now authored 345 peer-reviewed publications and 12 book chapters on BPH and minimally invasive surgical care. With such accolades, Dr. Zorn has become a sought-after speaker, teacher and researcher. He has travelled to lecture, teach and proctor surgery around the world, and is intimately involved with the development of several new, pioneering BPH technologies. Dr. Zorn attended McGill University for his pre-med Bachelor program, then completed his medical degree followed by residency in urological surgery at McGill. He became a fellow of the Royal College of Physicians and Surgeons of Canada in 2005. He has completed a two-year fellowship in oncology and endourology at the University of Chicago. In 2007, Dr. Zorn also became American Board of Urology certified in urology and a fellow of the American College of Surgeons. After remaining on faculty at the University of Chicago until 2009, Dr. Zorn returned to Canada in 2010 to join the faculty of the Division of Urology at the University of Montreal. As an attending urologist, he has cultivated a clinical and research interest in localized prostate cancer, robotic surgery (over 3500 robotic prostatectomy cases performed), artificial intelligence, men’s health, sexual dysfunction and BPH. He holds a number of roles including medical director of robotic surgery and fellowship director for robotics and MIS since 2011. He is also the founder of www.intuitiveurology.com (a global platform for resident urological education materials and self-testing) as well as www.BPHCanada.com (a comprehensive, personalize BPH surgical center to offer all Canadian men rapid access to all BPH surgical modalities). In summary, Dr. Zorn is a world-renown surgeon scientist in the field of urology who continues to make significant contributions to urological education, research and clinical BPH services.

Languages Spoken:

English, French, Spanish, German

Medical School:

McGill University

Residency:

McGill University

Fellowship:

University of Chicago

Undergraduate:

McGill University

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only